New Zealand Medicines Spending Report Urges Higher Funding

BERL estimated New Zealand would need to add about NZ$2.7 billion a year in medicine spending to reach the OECD benchmark, but said the payoff is substantial: the analysis found each dollar invested returns NZ$1.93 to the broader economy and NZ$1.15 to the Crown. It said the GDP benefit would overtake the cost within three years, while the fiscal payback to government would come over roughly 20 years through higher tax revenue and lower health-system costs.

For investors, the policy signal is a reminder that drug access and reimbursement remain central to the economics of the pharmaceutical sector. More public spending would support demand for newer medicines and could improve market access in a country that Business NZ says has been slower than comparable markets to approve and fund them.

The report also reinforces a broader global theme: governments trying to control health budgets are being pressed to treat medicine spending less as a cost and more as an investment in productivity. The argument is politically sensitive because it implies shifting existing health dollars toward pharmaceuticals rather than simply expanding the overall budget.

Business NZ said the report was aimed at policymakers, not drugmakers, even though it received funding from AbbVie, GSK and Roche. The lobbying push now raises the prospect of the issue becoming part of future budget and election debates, with any shift in funding priority likely to be watched closely by drug companies, hospitals and insurers.